Search Results

Kyverna Therapeutics, Inc. (Kyverna) announced today the publication in Proceedings of the National Academy of Sciences (PNAS)1 of a report describing the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS) as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies.

Moderna, Inc. announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering, broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the “development and manufacturing of pharmaceutical products, including the COVID-19 vaccine.”.

BlossomHill Therapeutics today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).

The Pontifical Academy of Sciences is proud to announce that Dr. Christina Rahm will be honored at its prestigious summit on May 29, 2024, at the Vatican. A distinguished scientist, entrepreneur, and philanthropist, Dr. Rahm has been recognized for her significant contributions to healthcare innovation and her unwavering commitment to improving global health.

In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the evolution of women’s inclusion in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.

In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.